Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy…

By Luisa Lina Villa, R. L. R. Costa, C. Petta, R. Andrade, K. Ault, A. Giuliano, C. Wheeler, L. Koutsky, C. Malm, M. Lehtinen and 19 more. The Lancet Oncology, 2005

1,716 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Obstetrics and Gynecology

View Paper: https://www.semanticscholar.org/paper/2b118b5e2aeee53c4fd25d36e444177324ce1a5b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Silvia Franceschi
2. G. Clifford
3. Luisa Lina Villa
4. L. Koutsky
5. S. Kjaer
6. M. Stanley

In Obstetrics and Gynecology

1. G. Clifford
2. Silvia Franceschi
3. R. Kurman

Citations in the corpus

• Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update (2007, background): “HPV11 was also considered on account of its inclusion in currently available quadrivalent HPV vaccines.(2) Each HPV type was evaluated independently of all others.”
• Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. (2010, methodology): “This population was restricted to subjects who received at least one injection of HPV6/11/16/18 vaccine or placebo and had any fol low-up after day 1 and, at enrollment, were seronegative (23–25) and negative (20,26,27) for HPV6, 11, 16, and 18 DNA; were negative for DNA from all 10 nonvaccine HPV t”